Biohit Oyj - Company Announcement

Notification of change in number of shares and voting rights, in accordance with the Securities Markets Act, Chapter 2, Section 10

On 19 August 2011, the total number of Biohit Oyj's shares and the voting
rights conferred by all shares changed as a result of a directed share issue
arranged to Sartorius Lab Holding GmbH. 

Following the share issue, the total number of Biohit shares is 13,615,593 and
the number of series B shares 10,640,093. The company's share capital totals
EUR 2,314,650.81. Following the issue, the total number of voting rights
conferred by all shares is 70 150 093. 

The shares were registered in the trade register and entered in the list of
Biohit's shareholders on 29 August 2011. Trading in the new shares will begin
on the stock market list of NASDAQ OMX Helsinki Ltd., together with other
Biohit shares, on 30 August 2011. 

Helsinki, 29 August 2011



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com

Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com



Biohit in brief:

 Biohit is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. The end users of Biohit's products are e.g. the
pharmaceutical industry, the food industry, research institutes and
universities as well as the public and private healthcare sectors. 

Biohit has two business segments: Liquid Handling and Diagnostics. Liquid
Handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services. The Diagnostics
business comprises products and analysis systems for the early diagnosis and
prevention of gastrointestinal diseases, such as the blood-sample based
GastroPanel examination for the diagnosis of stomach illnesses and associated
risks, and Acetium capsules, which bind carcinogenic acetaldehyde in the
stomach. 

In 2010, Biohit's net sales were MEUR 40 and the company employed approximately
400 people. Biohit is headquartered in Helsinki, Finland, and has production
facilities in Helsinki, Kajaani and in Suzhou, China. It has subsidiaries in
France, Germany, the UK, Russia, India, China, Japan and the USA. The company
also has a representative office in Singapore. Biohit's products are also sold
through about 200 distributors in 70 countries. 

Biohit's Series B share is quoted on NASDAQ OMX Helsinki in the Small
Cap/Healthcare group and is traded under the code BIOBV. 

More information: www.biohit.com.